Data from this study provides provocative evidence that, while BRAF+/−MEK inhibitor therapy produces an increase in overall and clonal T cell infiltrates, there is limited evidence for generation of new or persistent tumor immunity. This evidence concerns the gene BRAF and neoplasm.